PRNB - Principia Biopharma Inc.
Ask 40.97 x 800
EPS (TTM) N/A
1y Target Est N/A
Principia Biopharma Appoints Patrick Machado to Board of Directors
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of Patrick Machado to its Board of Directors. Mr. Machado brings significant operating experience, including his time as a co-founder, chief business officer and chief financial officer of Medivation, Inc., where he provided strong leadership in the development of XTANDI® and its successful commercial launch in prostate cancer.
Principia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder Cancer
The poster was presented at the AACR Bladder Cancer: Transforming the Field meeting in Denver, Colorado. This approach has the potential to enable selective and sustained inhibition of FGFR without the need to maintain high systemic exposure of the drug.
Principia Biopharma Announces First Patient Dosed in Sanofi's Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million Milestone
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that the first patient has been dosed in its partner Sanofi's Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS), triggering a $30 million milestone payment to Principia. SAR442168, formerly known as PRN2246, is a Bruton's tyrosine kinase (BTK) inhibitor that crosses the human blood-brain barrier and modulates immune cell function in both the periphery and in the brain, which shows promise for the potential treatment of central nervous system (CNS) diseases.
Principia Biopharma to Present at the 2019 Bank of America Merrill Lynch Health Care Conference
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 2019 Bank of America Merrill Lynch Health Care Conference on Wednesday, May 15, 2019, at 1:00pm PT (4:00pm ET) at the Encore Hotel in Las Vegas, Nevada. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with immune thrombocytopenia, a rare hematological disease.
Principia Biopharma Reports First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif., May 07, 2019 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies.
Principia Biopharma Appoints Shao-Lee Lin, M.D., Ph.D. to Board of Directors
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of industry veteran Shao-Lee Lin, M.D., Ph.D., a noted immunologist, rheumatologist, and allergist with significant biopharmaceutical development experience, to its Board of Directors. Dr. Lin is currently Executive Vice President, head of Research and Development and Chief Scientific Officer of Horizon Pharma plc., with past corporate experiences at AbbVie Inc., Gilead Sciences, Inc., and Amgen Inc.
Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., March 19, 2019 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral.
Principia Biopharma Reacquires Rights to Oral Immunoproteasome Program
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, announced a mutual agreement with AbbVie Biotechnology Limited (AbbVie) to end their collaboration aimed at developing oral immunoproteasome inhibitors and for Principia to reacquire the rights to the program. The two companies have agreed to conclude the collaboration effective March 2019. "AbbVie has completed an initial evaluation of Principia's highly selective, orally bioavailable covalent inhibitors of the immunoproteasome and, after an assessment of their biologic profiles relative to AbbVie's desired disease areas of focus, has determined that there is no longer a strategic fit," said Martin Babler, Chief Executive Officer of Principia.
Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced Phase 2 clinical data from the Believe-PV study for PRN1008 as part of the Late-breaking Research: Clinical Trials program at the American Academy of Dermatology (AAD) annual meeting in Washington D.C. PRN1008 is being developed for the potential treatment of pemphigus, including pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Confirming interim clinical results previously reported, the Phase 2 study reached the primary efficacy measurement of control of disease activity (CDA) on low dose corticosteroids.
Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, announced the presentation of Phase 1 clinical data for PRN2246, now known as SAR442168, at the American Consortium for Therapy and Research in Multiple Sclerosis (ACTRIMS) annual meeting in Dallas, Texas. PRN2246/SAR442168 is a Bruton's tyrosine kinase (BTK) inhibitor that crosses the blood-brain barrier and modulates immune cell function in both the periphery and in the brain. PRN2246/SAR442168 is being developed for the treatment of multiple sclerosis (MS) and potentially other central nervous system (CNS) diseases under a license agreement with Sanofi, a company committed to discovering and developing new treatment options for people living with MS.
Principia Biopharma Announces the Acceptance of Data from Phase 2 Pemphigus Vulgaris Trial as a Late-Breaking Presentation at 2019 American Academy of Dermatology Meeting
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that an abstract has been accepted for oral presentation at the Late-Breaking Research during the 2019 American Academy of Dermatology annual meeting in Washington, D.C. The abstract, "Final results of the Believe-PV proof of concept study of PRN1008 in pemphigus," will be presented as part of the Late-Breaking Research: Clinical Trials on Saturday, March 2, 2019 at 2:10pm ET in Ballroom A of the Walter E. Washington Convention Center. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.
Principia Biopharma to Present at 8th Annual SVB Leerink Global Healthcare Conference
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 8th Annual SVB Leerink global healthcare conference on Wednesday, February 27, 2019, at 10:00am ET at the Lotte New York Palace in New York City. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with immune thrombocytopenic purpura, a rare hematological disease.
Principia Biopharma Appoints John W. Smither to Board of Directors
Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of industry veteran John W. Smither, Chief Financial Officer of Sienna Biopharmaceuticals, Inc., to its Board of Directors and as chairperson of its Audit Committee. "John's expertise and counsel come at an exciting time for Principia as we pursue late-stage clinical development of our lead product candidate, PRN1008, in patients with pemphigus," said Martin Babler, Principia's Chief Executive Officer.
Principia Biopharma Issues Statement About the Passing of Board Member Lewis J. Shuster
Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology today issued the following statement: "It is with great sadness that we announce that Lewis (Lew) J. Shuster, a member of the company's board of directors, died last week due to recently diagnosed, late-stage pancreatic cancer. The entire Principia team mourns the loss of Lew and he will be dearly missed. Lew was a tremendously thoughtful and insightful board member, but more importantly, he was a kind and generous individual who brought a great deal of passion and energy to our industry and to the pursuit of our mission.
Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results and Initiates Phase 3 Pemphigus Program
Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced positive top-line data from the completed open-label Phase 2 trial of PRN1008 in patients with pemphigus (including both pemphigus vulgaris (PV) and pemphigus foliaceus (PF)) and the initiation of a Phase 3 trial of PRN1008 in pemphigus. The primary efficacy endpoint of the Phase 2 trial – Control of Disease Activity (CDA) within four weeks – was achieved by more than 50% of patients and PRN1008 was generally well tolerated.
Investor Expectations to Drive Momentum within Berkshire Hathaway, Zogenix, ICC, CIRCOR International, Principia Biopharma, and Technical Communications — Discovering Underlying Factors of Influence
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Principia Biopharma to Present at 27th Annual Credit Suisse Healthcare Conference
Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 27th Annual Credit Suisse Healthcare Conference on Thursday, November 15, 2018, at 8:35 a.m. MT (10:35 a.m. ET) at the Phoenician in Scottsdale, Arizona. The presentation will be available via live webcast from the "Events and Presentations" page of the "Investors" section of the Company's website. Principia Biopharma is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.
Principia Biopharma Reports Third Quarter Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral.
ACCESSWIRE•10 months ago
Today's Research Reports on Stocks to Watch: Unity Biotechnology and Principia Biopharma
NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Biotech stocks Unity Biotechnology and Principia Biopharma had exciting trading days on Friday. Shares of Unity saw more gains on Friday after exploding last Thursday when its CEO spoke on CNBC's "Power Lunch" about the company's plans. Amazon CEO Jeff Bezos is an investor in the company.